Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6427597 | 0.91 | ALDH1A1 (0.47) | ALDH1A1LMNAMEN1GAAMAPT | |
| SCHEMBL6388619 | 0.89 | LMNA (0.47) | ALDH1A1LMNAMEN1GAAMAPT | |
| SCHEMBL6506320 | 0.89 | L3MBTL1 (0.47) | ALDH1A1LMNAMEN1GAAMAPT | |
| SCHEMBL6427674 | 0.87 | MAPT (0.44) | ALDH1A1LMNAMEN1MAPTKMT2A | |
| SCHEMBL6428309 | 0.87 | GRM7 (0.46) | ALDH1A1GAAMAPTGRM7KDM4E | |
| SCHEMBL6501525 | 0.82 | TSHR (0.43) | ALDH1A1LMNAHTTMEN1GAA | |
| SCHEMBL6426299 | 0.81 | GRM7 (0.46) | ALDH1A1LMNAGAAMAPTKMT2A | |
| SCHEMBL6502545 | 0.81 | TSHR (0.53) | ALDH1A1MEN1GAAMAPTKMT2A | |
| SCHEMBL6506436 | 0.81 | TSHR (0.53) | ALDH1A1MEN1GAAMAPTKMT2A | |
| SCHEMBL6500660 | 0.81 | TSHR (0.53) | ALDH1A1MEN1GAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | ALDH1A1 67/4885LMNA 1964/4885HTT 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.